Microsphere-based long acting drug delivery products have been successfully used for over a decade. These depot formulations have distinct advantages, making them ideal for long-term sustained release applications. Subcutaneous injection of polymeric microspheres allows the intended drug to be released as the polymer slowly degrades, resulting in a continuous dose lasting up to four months. Because of this sustained release, doses are administered to patients less frequently than with other formulations. As patients may already have to endure numerous medications and treatments, the infrequency of these administrations helps to alleviate stress and minimizes the total amount of time spent receiving medication.
The depot formulations currently available by prescription include Decapeptyl LP, Zoladex®, Lupron Depot®, Profact® Depot®, Decapeptyl®, Suprecur® MP, Sandostain LAR® Depot, Nutropin Depot®, Arestin®, Atridox®, Eligard®, Trestar™ Depot, Somatuline® LA, Luprogel®, and Risperidal® Consta™. These formulations utilize several different drugs including Lupron and Risperdal.
The compound leuprolide acetate (trade name: Lupron) is a synthetic agonist of gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland; it is a more potent analog of the naturally produced GnRH. When administered to the human body, gonadotropin secretion is inhibited, leading to decreased functioning of the gonads and thus, a significantly decreased level of the sex hormones estradiol and testosterone in both males and females. This makes Lupron a useful compound for treating afflictions related to hormone levels, such as advanced prostate cancer (in which the tumors are dependent upon hormone levels), endometriosis, fibroids, and central precocious puberty. In 1989, the FDA approved the depot formulation of Lupron for palliative use and treatment of advanced prostate cancer; since then, depot formulations have been approved for the treatment of the other conditions listed above.
Risperidone (trade name: Risperdal) is a benzisoxazole derivative that acts as an antipsychotic agent in humans. Risperdal works by blocking dopamine receptors within the brain, preventing neurotransmitter overactivity. This blockage is particularly beneficial for treating illnesses such as schizophrenia, bipolar disorder, depression, and dementia.
The microspheres and microencapsulation services offered at Phosphorex can aid in the formulation of depot-based products employing many different drugs. For more information, please call (508) 435-9100 (toll free (877) 288-8010) or send an email to email@example.com.